A Phase 2 interventional study of bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag International NV. Completed at 21 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-30.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.
Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 47th largest by enrollment of the 267 interventional ones that give a count, is one of 17 that started in 2009, is one of 137 in phase 2, and was the 152nd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
Peking University First Hospital · Sites in China
Ages 18–70
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 176 · Phase 3 46 · Phase 4 8
First in 1999; this study’s year is marked. 17 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 267 interventional studies. Of the 194 that completed or were terminated, 94 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 271 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag International NV, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 57th largest by enrollment of the 100 interventional ones that give a count, is one of 5 that started in 2009, is one of 32 in phase 2, and was the 40th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
9 of the studies testing bortezomib in Multiple Myeloma that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT00734877Phase 3University of ArkansasUARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | 2027-09 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 271 studies testing bortezomib in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of bortezomib on myeloma-related bone disease, analyzing bone mineral density (BMD) in patients with Multiple Myeloma (MMY) who have received high dose chemotherapy and autologous stem cell transplantation for primary treatment of MMY (single- or double-transplant). Eligible patients will be randomized (study treatment assigned by chance like flipping a coin) to either bortezomib or observation alone. Patients in the bortezomib arm will receive treatment of bortezomib for a total of 4 cycles. All subjects will be followed for a total of 24 months after randomization.
This is a randomized, open-label (all people involved know the identity of the intervention), multicenter, multi-country parallel group study (each group of patients will be treated at the same time) in patients with Multiple Myeloma (MMY) who have received high dose chemotherapy and autologous stem cell transplantation for primary treatment of MMY (single- or double-transplant). The purpose of the study is to assess the effect of bortezomib on myeloma-related bone disease by analyzing bone mineral density. Approximately 80% of patients with MMY may experience myeloma-related bone disease. Myeloma-related bone disease may cause skeletal complications, including bone pain, bone lesions, abnormal fractures and super-elevated calcium concentrations in the blood. This study is investigating the safety and efficacy of an experimental drug, bortezomib, to consolidate the response to the primary treatment compared to no such consolidation treatment. The analyses in this study will be exploratory in nature, since the study will not address any pre-defined statements but is designed to generate valid hypotheses on safety and efficacy issues. Bortezomib is currently marketed for the treatment of different types of cancer including MMY. Bortezomib has been shown to promote bone formation and increase the number of bone-regenerating cells in preliminary studies. In the present study, the effect of bortezomib on bone formation will be assessed by dual energy x-ray absorptiometry (DXA) measuring bone mineral density, which is a measure for the quality of the bone structures. Several bone markers will be measured on serum samples. Bone markers are indicators of the bone activity. Patients will be evaluated for eligibility within a 14-day screening period, after providing written informed consent. Eligible patients will then be randomised to either bortezomib or observation alone. Baseline efficacy and safety assessments should be available on Cycle 1 Day 1 prior to administration of study medication. Randomization will be stratified by bisphosphonate treatment (use or not) at baseline and age (65 years or more versus less than 65 years). The treatment period is defined as the time the patient is actively receiving study treatment. Patients in the bortezomib arm will receive treatment of bortezomib for a total of 4 cycles or until start of alternative MMY treatment if earlier. Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive bortezomib 1.6 mg/m2 on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35). Bisphosphonate therapy can be administered as medically indicated and according to local practice. Patients are to attend study center visits on Days 1, 8, 15, and 22 of each treatment cycle or at Days 1, 36, 71, and 106 in the observation arm and at end of treatment (EOT) Visit. During these visits, different evaluations will be conducted to follow treatment safety: symptom directed physical examination, vital signs and laboratory tests. In addition, at Day 1 of Cycle 3 (prior to dosing) or Day 71 in the observation arm, patients will be assessed for disease progression or relapse by measurements of M-protein in serum and urine. If needed, absence of M-protein in serum and urine will be confirmed by immunofixation. Additional evaluations may be performed to document patient's clinical status and ability to tolerate additional therapy as clinically indicated. All patients will be followed for a total of 24 months since baseline. After end of the treatment phase, there will be a long-term follow-up period with visits at 4, 6, 12 and 18 months after the EOT Visit. In case the patient started alternative MMY treatment before completing the 18 months of follow-up, study assessments will stop, except for QoL assessments, which are to be continued up to 18 months of follow-up, and for a long-term follow-up for survival, which will be collected every 6 months by either a telephone call or a visit to the study site. The follow-up for survival will continue for all patients until the last patient has completed follow-up. In addition to scheduled visits, patients may have additional visits as clinically indicated. Every patient who was randomized should enter the long-term follow-up phase. Assessment of progressive disease (PD) or relapse from complete response (CR) should be performed according to the International Myeloma Working Group (IMWG) 2009 criteria. Changes in serum and urine M-protein (monoclonal paraprotein) levels will be confirmed by immunofixation in patients without measurable serum and urine M-protein levels. Karnofsky performance status will also be assessed. Safety will be assessed by monitoring of adverse events, physical examination (including neurological/peripheral neurological examinations), vital signs measurements and clinical laboratory tests. A total of two exploratory analyses will be performed for the present study: The first analysis (main analysis) will be presented after completion of the EOT Visit (24-weeks data). The second analysis will be the analysis at the end of the study on 18 months follow-up data. Patients in the bortezomib arm will receive treatment of bortezomib 1.6 mg/m² as a bolus infusion on Days 1, 8, 15, and 22 every 5 weeks for a total of 4 cycles
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
Drug: bortezomib
no treatment, observation only
Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
Change From Baseline in Bone Mineral Density (BMD) in the Spine at End of Treatment (EOT)
Change from baseline in bone mineral density (BMD) will be assessed by dual energy x-ray absorptiometry scans at baseline and the EOT visit
Time frame: at screening (i.e. between 14 and 1 days prior to start of treatment) and at end of treatment (EOT), i.e. 24 weeks after randomization or until start of alternative MMY therapy, if earlier
Change From Baseline in Bone Mineral Density (BMD) in the Femur at End of Treatment
Change from baseline in bone mineral density (BMD) will be assessed by dual energy x-ray absorptiometry scans at baseline and the end of treatment EOT visit
Time frame: at screening (i.e. between 14 and 1 days prior to start of treatment) and at end of treatment (EOT), i.e. 24 weeks after randomization or until start of alternative MMY therapy, if earlier
Progression Free Survival
The Progression-Free Survival (PFS) was assessed as median number of months from baseline until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Change From Baseline in Biochemical Bone Markers:Carboxyterminal Telopeptide of Type I Collagen (ICTP), Osteocalcin, Bone-specific Alkaline Phosphatase (BAP)
Bone markers (carboxyterminal telopeptide of type I collagen (ICTP), osteocalcin (Oc) and bone-specific alkaline phosphatase (BAP) was measured on serum samples.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Change From Baseline in Biochemical Bone Markers: Carboxyterminal Collagen Crosslinks (CTX-I)
Change from Baseline in Biochemical Bone Markers: CTX-I was assessed
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Change From Baseline in Biochemical Bone Markers: Dickkopf Homolog 1 (DKK-1)
Bone markers Dickkopf homolog 1 (DKK-1) was measured on serum samples.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Number of Patients With Skeletal Events
Number of patients with skeletal-related events (i.e. pathological fracture (vertebral, non-vertebral, combined), radiotherapy, spinal cord compression, orthopaedic surgery, hypercalcaemia) occurring over 24 months study period
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Appearance of New Bone Lesions Compared to Baseline
Appearance of new bone lesions assessed by skeletal survey compared to baseline
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Change From Baseline in Spine T-score
T score is used to calculate bone mineral density (calcium and other types of minerals) in an area of the bone. T score is the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as a participant. This score is calculated from participant's age, gender and race and skeletal site. T score has a mean of '50' and a standard deviation of '10'. T score lower than its mean indicate low bone mineral density.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Karnofsky Performance Status
The Karnofsky performance status is a way to quantify cancer patients' general well-being and activities of daily life and runs from 100 to 0, where 100 is "perfect" health and 0 is death.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Overall Survival
Overall survival defined as time from first treatment of MMY, i.e. day of first dose of induction therapy for MMY to date of death
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Change From Baseline in Quality of Life Assessed by Euro Quality of Life (EQ-5D)
Subjects were asked to rate their general state of health on a Visual analog scale (in millimeter \[mm\]) ranging from 0 (worst state of health) to 100 (best conceivable state of health) mm.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Tumor Response: Percentage of Participants With Very Good Partial Response (VGPR) or Stringent Complete Response (sCR) or Complete Response (CR) Based on International Myeloma Working Group (IMWG) Response Criteria
Tumor response was assessed as VGPR based on IMWG response criteria if, a) serum/urine M protein detectable by immunofixation but not on electrophoresis or; b) greater than or equal to 90% reduction in serum M protein plus urine M protein level less than 100 milligram/24 hour. CR=normal free light chain (FLC) ratio and absence of phenotypically aberrant plasma cells (PC) in bone marrow with a minimum of 3000 total PC analyzed by multiparametric flow cytometry; Complete response (CR) negative immunofixation on the serum and urine and, disappearance of any soft tissue plasmocytomas and \<5% plasma cells in bone marrow.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Tumor Response: Percentage of Participants With Stable Disease (SD) or Progressive Disease (PD) Based on International Myeloma Working Group (IMWG) Response Criteria
Tumor response was assessed as SD based on IMWG response criteria as not meeting criteria for CR, VGPR, PR, or progressive disease; PD as Increase of \>=25% from lowest response level in any one or more of the following: serum M protein (absolute increase \>=0.5 g/dl)c or urine M protein (absolute increase \>=200 mg/24 h); or serum/urine M protein unmeasurable: difference between involved and uninvolved free light chain (FLC) levels; absolute increase \>10 mg/dL; or % bone marrow plasma cells: absolute value \>=10% or definite development of new bone lesions or soft tissue plasmocytomas or definite increase in the size of existing bone lesions or soft tissue plasmocytomas; or development of hypercalcemia attributed solely to the plasma cell proliferative disorder.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
Tumor Response: Percentage of Participants With Partial Response (PR) Based on International Myeloma Working Group (IMWG) Response Criteria
Tumor response was assessed as PR based on IMWG response criteria as \>=50% reduction of serum and reduction in 24-h urinary M protein by \>=90% or to \<200 mg/24 h; or serum/urine M protein unmeasurable:\>=50% decrease in the difference between involved and uninvolved FLC levels; or serum/urine M protein and FLC assay unmeasurable: \>=50% reduction in plasma cells provided baseline bone marrow plasma cell percentage was \>=30%; or plus if present at baseline: \>=50% reduction in size of soft tissue plasmocytomas.
Time frame: Baseline up to end of study (approximately 4 years 7 months)
| Milestone | Bortezomib | Non-treated Control |
|---|---|---|
| Started | 51 | 53 |
| Completed | 41 | 46 |
| Not completed | 10 | 7 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Intercurrent illness | 1 | 0 |
| Withdrew: Non-compliance | 1 | 0 |
| Withdrew: The subject starts with alternative mmy | 0 | 3 |
| Withdrew: Patient's decision to stop treatment | 3 | 0 |
| Withdrew: Progression of disease | 0 | 1 |
| Withdrew: Refill medication not received in time | 1 | 0 |
Change from baseline in bone mineral density (BMD) will be assessed by dual energy x-ray absorptiometry scans at baseline and the EOT visit
| g/mm2 | Bortezomib | Non-treated Control |
|---|---|---|
| Change From Baseline in Bone Mineral Density (BMD) in the Spine at End of Treatment (EOT) | 0.0214 ± 0.0306 | 0.0167 ± 0.0301 |
Change from baseline in bone mineral density (BMD) will be assessed by dual energy x-ray absorptiometry scans at baseline and the end of treatment EOT visit
| g/mm2 | Bortezomib | Non-treated Control |
|---|---|---|
| Femur neck | 0.0053 ± 0.0221 | 0.0044 ± 0.0299 |
| Femur total | 0.0071 ± 0.0151 | 0.0138 ± 0.0288 |
The Progression-Free Survival (PFS) was assessed as median number of months from baseline until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier.
| Months | Bortezomib | Non-treated Control |
|---|---|---|
| Progression Free Survival | 39.56 ± 2.02 | 31.66 ± 1.81 |
Bone markers (carboxyterminal telopeptide of type I collagen (ICTP), osteocalcin (Oc) and bone-specific alkaline phosphatase (BAP) was measured on serum samples.
| Microgram per liter | Bortezomib | Non-treated Control |
|---|---|---|
| ICTP (n= 44, 42) | -4.11 ± 4.36 | -3.51 ± 3.81 |
| Osteocalcin (44, 42) | 20.15 ± 28.79 | 14.59 ± 5.57 |
| BAP (42, 40) | -0.48 ± 6.08 | -2.11 ± 4.80 |
Change from Baseline in Biochemical Bone Markers: CTX-I was assessed
| Nanogram per liter | Bortezomib | Non-treated Control |
|---|---|---|
| Change From Baseline in Biochemical Bone Markers: Carboxyterminal Collagen Crosslinks (CTX-I) | -66.50 ± 258.26 | -77.68 ± 158.23 |
Bone markers Dickkopf homolog 1 (DKK-1) was measured on serum samples.
| Picomole per liter | Bortezomib | Non-treated Control |
|---|---|---|
| Change From Baseline in Biochemical Bone Markers: Dickkopf Homolog 1 (DKK-1) | -39.31 ± 82.87 | -25.15 ± 87.20 |
Number of patients with skeletal-related events (i.e. pathological fracture (vertebral, non-vertebral, combined), radiotherapy, spinal cord compression, orthopaedic surgery, hypercalcaemia) occurring over 24 months study period
| patients | Bortezomib | Non-treated Control |
|---|---|---|
| Number of Patients With Skeletal Events | 0 | 0 |
Appearance of new bone lesions assessed by skeletal survey compared to baseline
| subjects | Bortezomib | Non-treated Control |
|---|---|---|
| Appearance of New Bone Lesions Compared to Baseline | 0 | 0 |
T score is used to calculate bone mineral density (calcium and other types of minerals) in an area of the bone. T score is the number of standard deviations above or below the mean for a healthy 30 year old adult of the same sex and ethnicity as a participant. This score is calculated from participant's age, gender and race and skeletal site. T score has a mean of '50' and a standard deviation of '10'. T score lower than its mean indicate low bone mineral density.
| T score | Bortezomib | Non-treated Control |
|---|---|---|
| Change From Baseline in Spine T-score | 1.2028 ± 0.2004 | 1.1811 ± 0.1689 |
The Karnofsky performance status is a way to quantify cancer patients' general well-being and activities of daily life and runs from 100 to 0, where 100 is "perfect" health and 0 is death.
| Units on a scale | Bortezomib | Non-treated Control |
|---|---|---|
| Screening | 92.4 ± 9.2 | 91.7 ± 7.0 |
| Follow-up | 0.0 ± 11.4 | 0.4 ± 7.5 |
Overall survival defined as time from first treatment of MMY, i.e. day of first dose of induction therapy for MMY to date of death
| Months | Bortezomib | Non-treated Control |
|---|---|---|
| Overall Survival | 49.90 ± 1.48 | 47.26 ± 1.26 |
Subjects were asked to rate their general state of health on a Visual analog scale (in millimeter \[mm\]) ranging from 0 (worst state of health) to 100 (best conceivable state of health) mm.
| millimeter (mm) | Bortezomib | Non-treated Control |
|---|---|---|
| Change From Baseline in Quality of Life Assessed by Euro Quality of Life (EQ-5D) | -0.3 ± 18.4 | 2.9 ± 22.6 |
Tumor response was assessed as VGPR based on IMWG response criteria if, a) serum/urine M protein detectable by immunofixation but not on electrophoresis or; b) greater than or equal to 90% reduction in serum M protein plus urine M protein level less than 100 milligram/24 hour. CR=normal free light chain (FLC) ratio and absence of phenotypically aberrant plasma cells (PC) in bone marrow with a minimum of 3000 total PC analyzed by multiparametric flow cytometry; Complete response (CR) negative immunofixation on the serum and urine and, disappearance of any soft tissue plasmocytomas and \<5% plasma cells in bone marrow.
| Percentage of participants | Bortezomib | Non-treated Control |
|---|---|---|
| Tumor Response: Percentage of Participants With Very Good Partial Response (VGPR) or Stringent Complete Response (sCR) or Complete Response (CR) Based on International Myeloma Working Group (IMWG) Response Criteria | 82.6 ± 1.48 | 72.3 ± 1.26 |
Tumor response was assessed as SD based on IMWG response criteria as not meeting criteria for CR, VGPR, PR, or progressive disease; PD as Increase of \>=25% from lowest response level in any one or more of the following: serum M protein (absolute increase \>=0.5 g/dl)c or urine M protein (absolute increase \>=200 mg/24 h); or serum/urine M protein unmeasurable: difference between involved and uninvolved free light chain (FLC) levels; absolute increase \>10 mg/dL; or % bone marrow plasma cells: absolute value \>=10% or definite development of new bone lesions or soft tissue plasmocytomas or definite increase in the size of existing bone lesions or soft tissue plasmocytomas; or development of hypercalcemia attributed solely to the plasma cell proliferative disorder.
| Percentage of participants | Bortezomib | Non-treated Control |
|---|---|---|
| Tumor Response: Percentage of Participants With Stable Disease (SD) or Progressive Disease (PD) Based on International Myeloma Working Group (IMWG) Response Criteria | 6.5 ± 1.48 | 19.1 ± 1.26 |
Tumor response was assessed as PR based on IMWG response criteria as \>=50% reduction of serum and reduction in 24-h urinary M protein by \>=90% or to \<200 mg/24 h; or serum/urine M protein unmeasurable:\>=50% decrease in the difference between involved and uninvolved FLC levels; or serum/urine M protein and FLC assay unmeasurable: \>=50% reduction in plasma cells provided baseline bone marrow plasma cell percentage was \>=30%; or plus if present at baseline: \>=50% reduction in size of soft tissue plasmocytomas.
| Percentage of participants | Bortezomib | Non-treated Control |
|---|---|---|
| Tumor Response: Percentage of Participants With Partial Response (PR) Based on International Myeloma Working Group (IMWG) Response Criteria | 8.7 ± 1.48 | 8.5 ± 1.26 |
Collected over from the time a signed and dated informed consent form is obtained until EOT Visit (24 weeks after randomization) or until the start of subsequent systemic antimyeloma therapy, if earlier. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bortezomib | — | 6/51 (11.8%) | 47/51 (92.2%) |
| Non-treated Control | — | 3/53 (5.7%) | 35/53 (66%) |
| Event | Bortezomib | Non-treated Control |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 1/51 | 0/53 |
| PyrexiaGeneral disorders | 1/51 | 0/53 |
| Acute hepatic failureHepatobiliary disorders | 1/51 | 0/53 |
| Device related infectionInfections and infestations | 1/51 | 0/53 |
| Herpes zosterInfections and infestations | 1/51 | 0/53 |
| Pneumonia bacterialInfections and infestations | 1/51 | 0/53 |
| Pancreatic neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 | 0/53 |
| AnaemiaBlood and lymphatic system disorders | 0/51 | 1/53 |
| BradycardiaCardiac disorders | 0/51 | 1/53 |
| Influenza like illnessGeneral disorders | 0/51 | 1/53 |
| Event | Bortezomib | Non-treated Control |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/51 | 0/53 |
| Peripheral sensory neuropathyNervous system disorders | 10/51 | 2/53 |
| NauseaGastrointestinal disorders | 9/51 | 0/53 |
| Upper respiratory tract infectionInfections and infestations | 9/51 | 9/53 |
| VomitingGastrointestinal disorders | 8/51 | 0/53 |
| PyrexiaGeneral disorders | 8/51 | 2/53 |
| FatigueGeneral disorders | 7/51 | 1/53 |
| NeutropeniaBlood and lymphatic system disorders | 6/51 | 1/53 |
| NasopharyngitisInfections and infestations | 6/51 | 4/53 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/51 | 0/53 |
| Age, Continuous(years) | Bortezomib | Non-treated Control | Total |
|---|---|---|---|
| Mean | 56.7 (27 to 75) | 54.7 (35 to 73) | 55.7 (27 to 75) |
| Sex: Female, Male(Participants) | Bortezomib | Non-treated Control | Total |
|---|---|---|---|
| Female | 18 | 22 | 40 |
| Male | 33 | 31 | 64 |
The record gives a start of Sep 2009, a primary completion of Nov 2012 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bortezomib
Janssen-Cilag International NV →